CARDIOME PHARMA CORP (CRME) reported quarterly earnings results on Tuesday, Aug-9-2016. The company reported $-0.37 earnings per share for the quarter, missing the analyst consensus estimate by $-0.17. Analysts had a consensus of $-0.20. The company posted revenue of $5.90 million in the period, compared to analysts expectations of $6.73 million. The company’s revenue was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.43 EPS.
Many Wall Street Analysts have commented on CARDIOME PHARMA CORP. H.C. Wainwright Initiated CARDIOME PHARMA CORP on Jun 1, 2016 to “Buy”, Price Target of the shares are set at $9.50.
CARDIOME PHARMA CORP opened for trading at $3.07 and hit $3.12 on the upside on Monday, eventually ending the session at $3.08, with a gain of 0.65% or 0.02 points. The heightened volatility saw the trading volume jump to 70,732 shares. Company has a market cap of $98 M.
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is focused on the development and commercialization of cardiovascular therapies that improve the life and health of patients suffering from heart disease. The Company has two marketed in-hospital cardiology products BRINAVESSTM and AGGRASTAT which are commercially available in markets outside of the United States. BRINAVESSTM (vernakalant (IV)) is approved in the European Union and is registered and approved in approximately 50 countries for the conversion of onset atrial fibrillation to sinus rhythm in adults (for non-surgery patients with atrial fibrillation of seven days or less) and for use in post-cardiac surgery patients with atrial fibrillation of three days or less. AGGRASTAT (tirofiban HCL) is a reversible GP IIb/IIIa inhibitor (an intravenous anti-platelet drug) for use in Acute Coronary Syndrome patients.